Cannabinoids

REFERENCES

• , Conant v. Waiters, 309 F.3d 629 (9th Cir. 2002)
   Google Scholar
• , Food and Drug Administration. Interagency advisory regarding claims that smoked marijuana is a medicine. Accessible at URL: http://www.fda.gov/bbs/topics/NEWS/2006/NEWO1362.html April 2004 (accessed October 30, 2006)
   Google Scholar
• Food and Drug Administration. Guidance for industry: Botanical drug products. US Government. 2004; 48, Services UDoHaH, éd.
   Google Scholar
• Di Marzo V. Cannabinoids. Springer, New York 2004
   Google Scholar
• Mechoulam R. Cannabinoids as therapeutics. Birkhiiuser Verlag, BaselSwitzerland 2005
   Google Scholar
• Guy G W, Whittle B, Robson P. The medicinal uses of cannabis and cannabinoids. Pharmaceutical Press, London 2004
   Google Scholar
• Russo E B, Grotenhermen F. Handbook of Cannabis Therapeutics: from Bench to Bedside. Haworth Press, Binghamton, NY 2006
   Google Scholar
• Pertwee R G. Receptors and pharmacodynamics: natural and synthetic cannabinoids and endocannabinoids. Me-dicinal uses of cannabis and cannabinoids, G W Guy, B A Whittle, P Robson. Pharmaceutical Press, London 2004; 103–40
   Google Scholar
• Pertwee R G. Cannabinoid receptors and pain. Prog Neurobiol. Apr, 2001; 63(5)569–611
   PubMed Web of Science ®Google Scholar
• Pertwee R G. Phamacological and therapeutic targets for delta-9-tetrahydrocannabinol and cannabidiol. Euphytica. 2004; 140: 73–82
   Web of Science ®Google Scholar
• Russo E B. The solution to the medicinal cannabis problem. Ethical issues in chronic pain management, M E Schatman. Taylor & Francis, Boca Raton, FL 2006, (in press)
   Google Scholar
• Russo E B, Guy G W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses. 2006; 66(2)234–46
   PubMed Web of Science ®Google Scholar
• Russo E B. Hemp for headache: An indepth historical and scientific review of cannabis in migraine treatment. Journal of Cannabis Therapeutics. 2001; 1(2)21–92
   Google Scholar
• Russo E B. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuroendocrinol Lett. Feb.-Apr., 2004; 25(1–2)31–9
   PubMed Web of Science ®Google Scholar
• Malfait A M, Gallily R, Sumariwalla P F, Malik A S, Andreakos E, Mechoulam R, et al. The non psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000; 97(17)9561–6
   PubMed Web of Science ®Google Scholar
• Carrier E J, Auchampach J A, Hillard C J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. May 16, 2006; 103(20)7895–900
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde D E, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanil-loid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. Oct, 2001; 134(4)845–52
   PubMed Web of Science ®Google Scholar
• Joy J E, Watson S J, Benson J A, Jr. Marijuana and medicine: Assessing the science base. Institute of Medicine, Washington, DC 1999; 201
   Google Scholar
• Noyes R., Jr., Baram D A. Cannabis analgesia. Compre Psychiatry 1974; 15(6)531–5
   PubMed Web of Science ®Google Scholar
• Noyes R, Jr., Brunk S F, Baram D A, Canter A C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical pharmacology and therapeutics. 1975; 18(1)84–9
   PubMed Web of Science ®Google Scholar
• Noyes R, Jr., Brunk S F, Baram D A, Canter A. Analgesic effect of delta-9- tetrahydrocannabinol. Journal of Clinical Pharmacology 1975; 15(2–3)139–43
   PubMed Web of Science ®Google Scholar
• Pertwee R G. The pharmacology and therapeutic potential of cannabidiol. Cannabinoids, V DiMarzo. Kluwer Academic Publishers, DordrechtNetherlands 2004; 32–83
   Google Scholar
• ElSoWy M A, Ross S A, Mehrnedic Z, Arafat R, Yi B, Banahan B F, 3rd. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J Forensic Sci. 2000; 45(1)24–30
   PubMed Web of Science ®Google Scholar
• McPartland J M, Russo E B. Cannabis and cannabis extracts: Greater than the sum of their parts?. Journal of Cannabis Therapeutics. 2001; 1(3–4)103–32
   Google Scholar
• Calhoun S R, Galloway G P, Smith D E. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998; 30(2)187–96
   PubMed Web of Science ®Google Scholar
• Svendsen K B, Jensen T S, Bach F W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. Jul 31, 2004; 329(7460)253
   PubMed Web of Science ®Google Scholar
• British Medical Association. Therapeutic uses of cannabis. Harwood Academic Publishers, Amsterdam 1997
   Google Scholar
• , Nabilone was approved in the US in 1988 for control of nausea and vomiting associated with cancer chemotherapy; however, it was never marketed by the original manufacturer. It was recently purchased by drug manufacturer Valeant, re-approved by the FDA for the same indication, and classified as a Schedule II drug
   Google Scholar
• Notcutt W, Price M, Chapman G. Clinical experience with nabilone for chronic pain. Pharmaceutical Sciences. 1997; 3: 551–5
   Google Scholar
• Berlach D M, Shir Y, Ware M A. Experience with the synthetic cannabinoid nabilone in chronic cancer pain. PainMed. Jan-Feb, 2006; 7(1)25–9
   Web of Science ®Google Scholar
• Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain: [Les effets de la nabilone, un cannabinoide synthétique, sur la douleur postopér-atoire]. Canadian Journal of Anaesthesia/Journal canadien d'anesthesie. Aug, 2006; 53(8)769–75
   Google Scholar
• Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290(13)1757–62
   PubMed Web of Science ®Google Scholar
• Dyson A, Peacock M, Chen A, Courade J P, Yaqoob M, Groarke A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain Jul, 2005; 116(1–2)129–37
   PubMed Web of Science ®Google Scholar
• Vann R E, Cook C D, Martin B R, Wiley J L. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther. 2007; 320(2)678–686
   PubMed Web of Science ®Google Scholar
• Campbell F A, Tramber M R, Carroll D, Reynolds D JM, Moore R A, McQuay H J. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. BMJ. 2001; 323(7 July)1–6
   PubMedGoogle Scholar
• Grinspoon L, Bakalar J B. Marihuana, the forbidden medicine. Rev. and exp. ed. Yale University Press, New Haven 1997
   Google Scholar
• Abrams Dl, Hilton J F, Leiser R J, Shade S B, Elbeik T A, Aweeka F T, et al. Shortterm effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann Intern Med. 2003; 139: 258–66
   PubMed Web of Science ®Google Scholar
• Abrams Dl, Jay C A, Vizoso H, Shade S B, Reda H, Press S, et al. Cannabis in HrV-associated sensory neuropathy: a randomized, placebo-controlled trial. Neurology 2007; 68: 515–21
   PubMed Web of Science ®Google Scholar
• Tashkin D P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis. Jun, 2005; 63(2)93–100
   PubMedGoogle Scholar
• Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. Journal of Cannabis Therapeutics. 2004; 4(1)7–27
   Google Scholar
• Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. Jun, 2006; 95(6)1308–17
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet Nov 8, 2003; 362(9395)1517–26
   PubMed Web of Science ®Google Scholar
• Zajicek J P, Sanders H P, Wright D E, Vickery P J, Ingram W M, Reilly S M, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry Dec, 2005; 76(12)1664–9
   PubMed Web of Science ®Google Scholar
• Ernst G, Denke C, Reif M, Schnelle M, Hagmeister H. Standardized cannabis extract in the treatment of postherpetic neuralgia: a randomized, double-blind, pla-cebo-controlled cross-over study. International Association for Cannabis as Medicine, LeidenNetherlands 2005, International Association for Cannabis as Medicine; 2005 September 9
   Google Scholar
• de Meijer E. The breeding of cannabis cultivars for pharmaceutical end uses. Medicinal uses of cannabis and cannabinoids, G W Guy, H A Whittle, P Robson. Pharmaceutical Press, London 2004; 55–70
   Google Scholar
• Guy G W, Robson P. A Phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CHME) administered sublingually-in variant cannabinoid ratios in normal healthy male volunteers (GWPK02125). Journal of Cannabis Therapeutics. 2003; 3(4)121–52
   Google Scholar
• Wade D T, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation. 2003; 17: 18–26
   Web of Science ®Google Scholar
• Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmonds S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies. Anaesthesia. 2004; 59: 440–52
   PubMed Web of Science ®Google Scholar
• Bemlan J S, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain Dec, 2004; 112(3)299–306
   PubMed Web of Science ®Google Scholar
• Rogill Nurmiko T, Friede T, Young C. Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis. Neurology 2005; 65(6)812–9
   PubMed Web of Science ®Google Scholar
• Nurmikko T J, Serpell M G, Hoggart B, Toomey P J, Morlion B J. A multi-center, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. American Academy of Neurology April 14, 2005, Miami Beach, FL; 2005
   PubMedGoogle Scholar
• Wade D T, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double- blind, randomized, placebo-controlled study on 160 patients. Mult Scler. Aug, 2004; 10(4)434–41
   PubMed Web of Science ®Google Scholar
• Blake D R, Robson P, Ho M, Jubb R W, McCabe C S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatol (Oxford) Jan, 2006; 45(1)50–2
   PubMed Web of Science ®Google Scholar
• Johnson J R, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. British Pain Society March 8–11, 2005, Edinburgh, Scotland; 2005
   Google Scholar
• Wade D T, Makela P M, House H, Bateman C, Robson P J. Long-term use of cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis. Oct., 2006; 12(5)639–45
   PubMed Web of Science ®Google Scholar
• Martin B R, Wiley J L. Mechanism of action in cannabinoids: how it may lead to treatment of cachexia, emesis and pain. Supportive Oncology July/August, 2004; 2(4)305–16
   PubMedGoogle Scholar
• Pertwee R G. Cannabinoids and the gastrointestinal tract. Gut. Jun, 2001; 48(6)859–67
   PubMed Web of Science ®Google Scholar
• Pertwee R G. Cannabidiol as a potential medicine. Cannabinoids as therapeutics, R Mechoulam. Birkhauser Verlag, BaselSwitzerland 2005; 47–65
   Google Scholar
• Cichewicz D, Welch S P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral delta-9-tetrahydrocannabinol. J Pharmacol ExpTher 2003; 305(3)812–17
   PubMed Web of Science ®Google Scholar
• Cichewicz D L, Martin Z L, Smith F L, Welch S P. Enhancement of mu opioid antinociception by oral delta-9-tetrahydrocannabinol: Doseresponse analysis and receptor identification. J Pharmacol Exp Ther. 1999; 289(2)859–67
   PubMed Web of Science ®Google Scholar
• Cichewicz D L, McCarthy E A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. Mar, 2003; 304(3)1010–5
   PubMed Web of Science ®Google Scholar
• Roberts Gennings C, III, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530: 54–8
   PubMed Web of Science ®Google Scholar
• Lynch M A, Clark Al. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage. 2003; 25: 496–8
   PubMed Web of Science ®Google Scholar
• Sutton I R, Daeninck P. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. Supportive Oncology 2006; 4(1)531–5
   PubMedGoogle Scholar
• Buggy Dl, Toogood L, Marie S, Sharpe P, Lambert D G. Rowbotham ill. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain Nov, 2003; 106(1–2)169–72
   PubMed Web of Science ®Google Scholar
• Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology May, 2006; 104(5)1040–6
   PubMed Web of Science ®Google Scholar
• Pertwee R G. Cannabinoids and the gastrointestinal tract. Gut. Jun, 2001; 48(6)859–67
   PubMed Web of Science ®Google Scholar
• Roth M D, Marques-Magallanes I A, Yuan M, Sun W, Tashkin D P, Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol. 2001; 24(3)339–44
   PubMed Web of Science ®Google Scholar
• McKallip R J, Lombard C, Fisher M, Martin B R, Ryu S, Grant S, et al. Targeting CB2 cannabinoidreceptors as a novel therapy to treat malignant lymphoblastic disease. Blood. Jul 15, 2002; 100(2)627–34
   PubMed Web of Science ®Google Scholar
• Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. Sep 25, 1998; 436(1)6–10
   PubMed Web of Science ®Google Scholar
• Casanova M L, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero M J, Huffman J W, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. Jan, 2003; 111(1)43–50
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 1998; 95(14)8375–80
   PubMed Web of Science ®Google Scholar
• Sarker K P, Biswas K K, Yamakuchi M, Lee K Y, Hahiguchi T, Kracht M, et al. ASKl-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC 12 cell death. J Neurochem. Apr, 2003; 85(1)50–61
   PubMed Web of Science ®Google Scholar
• Vaccani A, Massi P, Parolaro D. Inhibition of human glioma cell growth by the non psychoactive cannabidiol. First European Workshop on Cannabinoid Research April 4–5, 2003; 66, Madrid; 2003
   Google Scholar
• Maccarrone M, Finazzi-Agro A. The endocannabinoid system, anandamide and the regulation of mam-malian cell apoptosis. Cell Death Differ. Sep, 2003; 10(9)946–55
   PubMed Web of Science ®Google Scholar
• Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer Oct, 2003; 3(10)745–55
   PubMed Web of Science ®Google Scholar
• Kogan N M. Cannabinoids and cancer. Mini Rev MedChem. Oct, 2005; 5(10)941–52
   PubMed Web of Science ®Google Scholar
• Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova M L, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. Aug 15, 2004; 64(16)5617–23
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Bifulco M, Ligresti A, Di Marzo V. Potential use of cannabimimetics in the treatment of cancer. Cannabinoids as therapeutics, R Mechoulam. Birkhauser Verlag, BaselSwitzerland 2005; 165–81
   Google Scholar
• Hampson A J, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998; 95(14)8268–73
   PubMed Web of Science ®Google Scholar
• Maas A I, Murray G, Henney H, 3rd, Kassem N, Legrand V, Mangelus M, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. Jan, 2006; 5(1)38–45, Initial therapeutic trials of dexanabinol, a non-psychoactive synthetic cannabinoid, in closed head injury demonstrated clinical benefit, but a subsequent Phase, III trial found it to be ineffective
   PubMed Web of Science ®Google Scholar
• Glass M. The role of cannabinoids in neuro-degenerative diseases. Prog Neuropsychopharmacol Biol Psychiatr. 2001; 25(4)743–65
   PubMedGoogle Scholar
• Volicer L, Stelly M, Morris J, McLaughlin J, Volicer B J. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatr. 1997; 12(9)913–9
   PubMed Web of Science ®Google Scholar
• Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) May, 2006; 185(4)524–8
   PubMed Web of Science ®Google Scholar
• Ramirez B G, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos M L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. Feb23, 2005; 25(8)1904–13
   PubMed Web of Science ®Google Scholar
• Glass M, Dragunow M, Faull R L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. NeuroScience 2000; 97(3)505–19
   PubMed Web of Science ®Google Scholar
• Venderova K, Ruzicka E, Vorisek V, Visnovsky P. Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. Mov Disord. Sep, 2004; 19(9)1102
   PubMed Web of Science ®Google Scholar
• Venderova K, Brown T M, Brotchie J M. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Exp Neurol. Jul, 2005; 194(1)284–7
   PubMed Web of Science ®Google Scholar
• Consroe P, Snider S R. Therapeutic potential of cannabinoids in neurological disorders. Cannabinoids as therapeutic agents, R Mechoulam. CRC Press, Boca Raton, FL 1986; 21–49
   Google Scholar
• Carter G T, Rosen B S. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliât Care. 2001; 18(4)264–70
   PubMedGoogle Scholar
• Raman C, McAllister S D, Rizvi G, Patel S G, Moore D H, Abood M E. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. ALS and Other Motor Neuron Disorders. 2004; 5: 33–9
   PubMed Web of Science ®Google Scholar
• Abood M E, Raman C, Kim K, Moore D H. Evaluation of cannabidiol in a mutant SOD1 mouse model of ALS. International Alliance of ALS/MND Associations, Philadelphia 2004, December 3; 2004
   Google Scholar